Immunotherapies Based on Tumor Classification
All materials on this site are thoughtfully organized by tumor type for your convenience. Our goal is to provide you with comprehensive information and resources about immunotherapy treatments for various types of cancer. Our team of experts continuously updates this website to ensure that you have access to accurate, evidence-based information.
Acute Lymphocytic Leukemia
- Blinatumomab
- Brexucabtagene Autoleucel
- Obecabtagene Autoleucel
- Tisagenlecleucel
Agnostic
- Dostarlimab-gxly
- Fam-trastuzumab Deruxtecan
- Pembrolizumab
Alveolar Soft Part Sarcoma
- Atezolizumab
Basal Cell Carcinoma
- Cemiplimab
Bile Duct and Gallbladder Cancer
- Durvalumab
- Pembrolizumab
- Tremelimumab-actl
Bladder Cancer
- Bacillus Calmette-Guérin (BCG)
- Nadofaragene Firadenovec-vncg
- Nogapendekin Alfa-inbakicept
- Pembrolizumab
Blastic Plasmacytoid Dendritic Cell Neoplasm
- Tagraxofusp
Breast Cancer
- Fam-trastuzumab Deruxtecan
- Pembrolizumab
Cervical Cancer
- Atezolizumab
- Pembrolizumab
- Tisotumab Vedotin-tftv
Colon Cancer
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Pembrolizumab
Cutaneous Squamous Cell Carcinoma
- Cemiplimab
- Cosibelimab
- Pembrolizumab
Endometrial Cancer
- Dostarlimab-gxly
- Durvalumab
- Pembrolizumab
- Tremelimumab-actl
Esophageal Cancer
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Pembrolizumab
Gastric Cancer
- Fam-trastuzumab Deruxtecan
- Nivolumab
- Pembrolizumab
Hepatocellular Carcinoma
- Atezolizumab
- Durvalumab
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Pembrolizumab
- Tremelimumab-actl
Head Neck Cancer
- Nivolumab
- Pembrolizumab
Hodgkin Lymphoma
- Nivolumab
- Pembrolizumab
Lymphoma
- Axicabtagene Ciloleucel
- Brexucabtagene Autoleucel
- Epcoritamab-bysp
- Glofitamab-gxbm
- Lisocabtagene Maraleucel
- Mosunetuzumab-axgb
- Pembrolizumab
- Tafasitamab-cxix
- Tisagenlecleucel
Melanoma
- Atezolizumab (in combination with cobimetinib and vemurafenib)
- IL-2
- Ipilimumab
- Ipilimumab/Nivolumab
- Lifileucel
- Nivolumab
- Pembrolizumab
- Relatlimab/Nivolumab
- T-VEC
- Tebentafusp-tebn
Merkel Cell Carcinoma
- Avelumab
- Pembrolizumab
- Retifanlimab-dlwr
Mesothelioma
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Pembrolizumab
Multiple Myeloma
- Ciltacabtagene Autoleucel
- Daratumumab
- Idecabtagene Vicleucel
- Isatuximab-irfc
- Talquetamab-tgvs
- Teclistamab-cqyv
Nasopharyngeal Cancer
- Toripalimab-tpzi
Non-Small Cell Lung Cancer
- Atezolizumab
- Cemiplimab
- Durvalumab
- Fam-trastuzumab Deruxtecan
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Pembrolizumab
- Tremelimumab-actl
Pancreatic Cancer
- None at the time this page was last updated
Prostate Cancer
- Sipuleucel-T
Small Cell Lung Cancer
- Atezolizumab
- Durvalumab
- Tarlatamab-dlle
- Tremelimumab-actl
Renal Cell Carcinoma
- Avelumab
- IL-2
- Ipilimumab
- Ipilimumab/Nivolumab
- Nivolumab
- Pembrolizumab
Urothelial Carcinoma
- Avelumab
- Nivolumab
- Pembrolizumab
Some tests may be required, such as mismatch repair deficiency, HER-2+(IHC 3+) solid tumor.
Some therapeutics require combinations, not monotherapy, for their FDA-approved indications.